Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Stock ScreenerScreener ETF ScreenerETF Maps Charts News Groups Insider Futures Forex Crypto Watchlist Portfolio Calendar
Pricing

FTH

Faeth Therapeutics Inc

Last Close
19.92
Nov 05 • 3:59 PM ET Dollar change-0.07 Percentage change(-0.35%)
Aftermarket Close
19.92
Aftermarket • 4:15 PM ET Dollar change0.00 Percentage change(0.00%)
Overview Compare Short Interest Financials Options Filings Dilution
Healthcare Biotechnology USA Small NASD
Peers: CELC RLAY BBOT OLMA ARVN KURA IDYA TNGX ATOS CNTX
 | Held by: VTI VXF XBI SCHA IWC ITOT SCHB LABU ONEQ AVSC
Scroll to Statements
Index
-
Market Cap
514.81M
Enterprise Value
346.93M
Income
-211.36M
Sales
0.00M
Book/sh
6.23
Cash/sh
6.76
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
29
IPO
Feb 04, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
3.20
P/C
2.95
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
16.12
Current Ratio
16.12
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-138.82
EPS next Y
-3.48
EPS next Q
-0.83
EPS this Y
12.07%
EPS next Y
76.35%
EPS next 5Y
40.51%
EPS past 3/5Y
19.15% -4.83%
Sales past 3/5Y
- -
EPS Y/Y TTM
-624.45%
Sales Y/Y TTM
-
EPS Q/Q
78.21%
Sales Q/Q
-
Earnings
Nov 03 BMO
EPS/Sales Surpr.
-1.07% -
Insider Own
28.82%
Insider Trans
0.32%
Inst Own
49.54%
Inst Trans
56.80%
ROA
-204.67%
ROE
-221.47%
ROIC
-125.91%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-0.29%
SMA50
-28.07%
SMA200
-21.35%
Trades
Shs Outstand
25.84M
Shs Float
18.39M
Short Float
12.62%
Short Ratio
6.37
Short Interest
2.32M
52W High
42.14 -52.73%
52W Low
7.45 167.38%
Volatility
8.01% 10.64%
ATR (14)
2.15
RSI (14)
40.55
Beta
-0.18
Rel Volume
0.74
Avg Volume
364.54K
Volume
270,620
Perf Week
6.24%
Perf Month
-20.06%
Perf Quarter
-18.33%
Perf Half Y
-16.16%
Perf YTD
86.69%
Perf Year
124.58%
Perf 3Y
44.35%
Perf 5Y
-88.83%
Perf 10Y
-
Recom
1.12
Target Price
56.07
Prev Close
19.99
Price
19.92
Change %
-0.35%
Consensus
Strong Buy
Avg. Price Target
$56.07
Implied Upside
+181.5%
Analysts16incl. previous ratings
Rating Distribution15 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 16, 2026Initiated
WWilliam Blair
Outperform
Sep 16, 2026Initiated
GGuggenheim
Buy$70+251.4%
Sep 09, 2026Initiated
TD logoTTD Cowen
Buy
Aug 21, 2026Initiated
NNeedham
Buy$56+181.1%
Jul 31, 2026Initiated
RJF logoRRaymond James
Outperform$56+181.1%
Jul 28, 2026Initiated
OPY logoOOppenheimer
Outperform$60+201.2%
Jul 20, 2026Initiated
CCitizens
Mkt Outperform$51+156.0%
Jun 26, 2026Initiated
RRobert W. Baird
Outperform$57+186.1%
Jun 22, 2026Initiated
HH.C. Wainwright
Buy$60+201.2%
Jun 11, 2026Initiated
BBTIG Research
Buy$55+176.1%
Show Previous News
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cambrian BioPharma Inc10% OwnerJul 22 '26Proposed Sale27.99130,1423,642,675Aug 11 12:52 PM
STEPHENSON BRIAN CChief Financial OfficerJun 30 '26Buy24.257,803189,24041,688Jul 01 08:09 PM
STEPHENSON BRIAN CChief Financial OfficerJul 01 '26Buy23.505,000117,49246,688Jul 01 08:09 PM
STEPHENSON BRIAN CChief Financial OfficerJun 29 '26Buy23.3483119,39633,885Jul 01 08:09 PM
STEPHENSON BRIAN CChief Financial OfficerJun 24 '26Buy26.139,391245,36026,804Jun 26 07:40 PM
STEPHENSON BRIAN CChief Financial OfficerJun 26 '26Buy24.956,250155,90833,054Jun 26 07:40 PM
STEPHENSON BRIAN CChief Financial OfficerJun 23 '26Buy24.369,230224,80617,413Jun 24 06:58 PM
STEPHENSON BRIAN CChief Financial OfficerJun 22 '26Buy22.138,183181,1158,183Jun 24 06:58 PM
Parikh Anand KiranPresident and CEOJun 22 '26Option Exercise1.1653,46562,019817,699Jun 24 06:55 PM
Parikh Anand KiranPresident and CEOJun 22 '26Buy19.762,80655,447764,234Jun 24 06:55 PM
Cambrian BioPharma Inc10% OwnerJun 01 '26Sale20.0225,000500,543130,142Jun 01 05:21 PM
Peyer James10% OwnerJun 01 '26Sale20.0225,000500,543130,142Jun 01 05:20 PM
MILLENNIUM MANAGEMENT LLC10% OwnerApr 02 '26Buy35.012,00370,133144,974May 15 04:24 PM
MILLENNIUM MANAGEMENT LLC10% OwnerApr 07 '26Buy33.381,10836,985133,986May 15 04:24 PM
MILLENNIUM MANAGEMENT LLC10% OwnerApr 06 '26Buy31.021,10434,246141,029May 15 04:24 PM
MILLENNIUM MANAGEMENT LLC10% OwnerApr 07 '26Sale31.018,151252,775133,986May 15 04:24 PM
MILLENNIUM MANAGEMENT LLC10% OwnerApr 02 '26Sale32.127,666246,239144,974May 15 04:24 PM
MILLENNIUM MANAGEMENT LLC10% OwnerApr 06 '26Sale31.061,25939,100141,029May 15 04:24 PM
MILLENNIUM MANAGEMENT LLC10% OwnerApr 01 '26Buy34.496,175212,979147,731May 15 04:22 PM
MILLENNIUM MANAGEMENT LLC10% OwnerMar 31 '26Buy28.166,005169,121146,657May 15 04:22 PM
MILLENNIUM MANAGEMENT LLC10% OwnerMar 31 '26Sale25.491,59140,553146,657May 15 04:22 PM
MILLENNIUM MANAGEMENT LLC10% OwnerApr 01 '26Sale31.651,15036,396147,731May 15 04:22 PM
MILLENNIUM MANAGEMENT LLC10% OwnerMar 27 '26Buy26.6115,321407,717142,360May 15 04:22 PM
MILLENNIUM MANAGEMENT LLC10% OwnerMar 30 '26Buy25.869,533246,495145,678May 15 04:22 PM
MILLENNIUM MANAGEMENT LLC10% OwnerMar 26 '26Buy28.625,731164,045131,370May 15 04:22 PM
MILLENNIUM MANAGEMENT LLC10% OwnerMar 26 '26Sale28.121,85752,220131,370May 15 04:22 PM
MILLENNIUM MANAGEMENT LLC10% OwnerMar 30 '26Sale26.6188823,632145,678May 15 04:22 PM
MILLENNIUM MANAGEMENT LLC10% OwnerMar 27 '26Sale26.8150513,538142,360May 15 04:22 PM
Cambrian BioPharma Inc10% OwnerApr 29 '26Proposed Sale31.95155,1424,956,786Apr 29 03:26 PM
Celebi JohnFormer OfficerFeb 24 '26Proposed Sale34.493,374116,356Feb 24 04:11 PM
Peyer JamesFomer Director Feb 18 '26Proposed Sale27.1395025,769Feb 18 01:22 PM
RINGO WILLIAM RFormer DirectorJan 27 '26Proposed Sale9.831,16911,486Jan 27 05:33 PM
Cambrian BioPharma Inc10% OwnerDec 09 '25Option Exercise6.403952,528155,983Dec 10 04:56 PM
Cambrian BioPharma Inc10% OwnerDec 09 '25Sale8.256,61254,575155,142Dec 10 04:56 PM
Peyer James10% OwnerDec 09 '25Option Exercise6.403952,528155,983Dec 10 04:52 PM
Peyer James10% OwnerDec 09 '25Sale7.963,50727,903155,142Dec 10 04:52 PM
Peyer James10% OwnerDec 08 '25Sale8.593,10526,672158,254Dec 10 04:52 PM
Peyer JamesFormer DirectorDec 09 '25Proposed Sale7.978416,707Dec 09 12:20 PM
Cambrian BioPharma Inc10% OwnerDec 05 '25Sale11.5016,295187,390161,359Dec 08 04:39 PM
Cambrian BioPharma Inc10% OwnerDec 04 '25Sale9.065,00045,300177,654Dec 08 04:39 PM
Peyer James10% OwnerDec 05 '25Sale11.5016,295187,390161,359Dec 08 04:36 PM
Peyer James10% OwnerDec 04 '25Sale9.065,00045,300177,654Dec 08 04:36 PM
Cambrian BioPharma Inc10% OwnerDec 04 '25Proposed Sale8.715,84450,901Dec 04 04:18 PM
Cambrian BioPharma Inc10% OwnerDec 04 '25Proposed Sale8.7121,222184,843Dec 04 03:41 PM
Faeth Therapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Austin, TX.
Senior VP of FinanceMr. Josiah Craver CPA
General Counsel & SecretaryMr. Christopher W. Gerry J.D.
J.D.Mr. Anand Parikh Esq.
M.D.Dr. Siddhartha Mukherjee DPHIL
Scientific Co-FounderDr. Lewis clayton Cantley Ph.D.
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)